Tetrahedron 66 (2010) 758-764

Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Oxaphospholene and oxaphosphinene heterocycles via RCM using unsymmetrical phosphonates or functional phosphinates

Pierre Fourgeaud^a, Camille Midrier^a, Jean-Pierre Vors^b, Jean-Noël Volle^a, Jean-Luc Pirat^a, David Virieux^{a,*}

^a Institut Charles Gerhardt–UMR5253–AM2N–ENSCM, 8, Rue de l'Ecole Normale, F34296 Montpellier Cedex 5, France ^b Bayer CropScience, 14-20 rue Pierre Baizet, BP 9163, F69263 Lyon Cedex 09, France

ARTICLE INFO

Article history: Received 7 September 2009 Received in revised form 6 November 2009 Accepted 10 November 2009 Available online 14 November 2009

ABSTRACT

New phosphorus heterocycles were synthesized using RCM reaction. They were prepared from unsymmetrical or polyfunctional insaturated precursor in 50 to 87% yields solving the problem of possible competitive side reactions. In parallel hydroxyphosphinate scaffolds represent a versatile starting material and could be of great interest for the synthesis of phosphosugar libraries.

© 2009 Elsevier Ltd. All rights reserved.

Tetrahedror

1. Introduction

Due to their key roles in cells metabolism and their potential to serve as pharmaceuticals and agricultural agents, phosphorus molecules are popular targets for the development of new biologically active compounds.¹ General methods to synthesize phosphorus heterocycles (P-heterocycles) employing functional group-compatible transition-metal catalyzed processes were a key achievement of the last few years.² Among them, the advent of ring-closing metathesis (RCM)³ as a core synthetic tool has led to numerous advances in the preparation of small phosphorus molecules.⁴ However, synthesis of *P*-heterocycles by such way is sometimes clearly impeded by competitive side reactions: So far if diallyl allylphosphonates mainly furnished the more favored sixoxaphospholenes, symmetrical diallyl membered vinylphosphonates led competitively to the formation of both five- and six-membered P-heterocycles and were consequently not easily purified.⁵ Besides in an interesting piece of work, Hanson synthesized phosphonosugars (cyclic phosphonates) utilizing the RCM reaction. Then, subsequent epoxidation followed by opening of the epoxide resulted in the formation of the oxaphosphinene containing a hydroxyl group which required two more linear steps from the ring formation.⁶

These findings suggest that the search for novel unsymmetrical and/or functional unsaturated phosphorus precursors is highly desirable as illustrated by recently patented anticancer oxaphosphinanes.⁷ As part of a program aimed at developing the construction of diverse phosphorus-containing heterocycles as potential fungicides, we herein report the RCM reaction of

unsymmetrical phosphonates or functional 1-hydroxyphosphinates with as features the presence of two different functional alkenyl groups directly linked to the phosphorus atom.

2. Results and discussion

2.1. Preparation of unsaturated functional precursors

Vinyl- or allylphosphonochloridates were the key intermediates and they constituted a really affordable unsymmetrical phosphorus reagent.

The synthesis of unsymmetrical allyl vinylphosphonates was performed according to the Scheme 1. Firstly the reaction of triethyl phosphite with 1-bromo-2-chloroethane led to diethyl 2-chloroethylphosphonate which was reacted with alcoholic potassium hydroxide affording diethyl vinylphosphonate **1** in 80% yield. Then, selective monochlorination using oxalyl chloride gave ethyl



Scheme 1. Synthesis of unsymmetrical allyl vinylphosphonates 3a, b.



^{*} Corresponding author. Tel.: +33 467 144 314; fax: +33 467 144 319. *E-mail address*: david.virieux@enscm.fr (D. Virieux).

vinylphosphonochloridate **2** in 96% yield. The final step used either allylic alcohol or *N*-allyl-*N*-benzylamine in order to obtain the precursors **3a**, **b**, respectively in 67% and 50% yields.

Allyl allylphosphonates were obtained using a similar approach. The Arbuzov reaction of triethyl phosphite with commercial allyl halides afforded the corresponding allylphosphonates 4a-c in yields ranging from 58 to 85%. After the quantitative formation of phosphonochloridate 5a-c, their reactions with allylic alcohols or *N*-allyl-*N*-benzylamine gave precursors 6a-c in 46–67% yields, Scheme 2.



Scheme 2. Synthesis of unsymmetrical allyl allylphosphonates 6a-c.

Synthesis of functional allyl allylphosphinates **8a–d** was performed by another way starting from phenylphosphinic acid. The esterification of acid took place using a modified Hewitt reaction in 79% yield.⁸ Then, the Pudovik additions of H–phenylphosphinate to α,β -unsaturated ketones or aldehydes, using potassium fluoride as a base, led to the functional α -hydroxyphosphinates **6d–g** in 39– 73% yields.⁹ No diastereoselectivity was observed during those reactions and the resulting products were obtained with low diastereomeric excess. On the other hand, the competitive Michael addition product was only obtained in 21% yield when methylvinylketone was reacted with **7**. However, it was easily removed after purification by flash chromatography on silica, Scheme 3.



Scheme 3. Synthesis of allyl α-hydroxyallylphosphinates 6d-g.

2.2. Ring closure metathesis reactions

The first generation Grubbs' catalyst was used in refluxing dichloromethane to perform the RCM reaction. Scope and limitations were given in Scheme 4 and Table 1. The reaction of alkenylphosphonates or phosphinates was sometimes tricky but the yields were ranging from 50 and up to 87%. When the reaction

failed, starting material was recovered after chromatography showing that no reaction and no degradation occurred.



Scheme 4. RCM reaction of unsymmetrical and functional precursors 3a, b or 6a-g.

Table	1							
RCM r	eaction	products	from	unsymmetrical	and	hydroxy	precursors	

	Precursor	Product	% Catalyst	Time	Yield (%)
8a		О Р-ОН О	7	2 h	64
8b	O P-OEt N-Ph	O P-OEt N Ph	2	30 min	80
9a			5	2 h 30 min	87
9b			10	48 h	0
9c	EtO-P Ph_N	EtO-P Ph_N	2.5	30 min	75
9d	Ph-P-	Ph-P O	7.5	2 h	70
9e	Ph-P-C-	Ph-P O O Me	12	76 h	0
9f	Ph-P-	Ph-P	10	3 h	50
9g	Ph-P- Br	Ph-P O O Br	12	120 h	0

Five membered oxaphospholene ester **8a** was not stable and was readily hydrolyzed by air moisture into its acid form in 64% yield as Machida observed with similar structures.¹⁰ Surprisingly, azaphospholene ester **8b** was quite stable on fast chromatography but it was transformed on storage through a phosphorus–nitrogen bond cleavage.

Substrates having halogen on double bond did not undergo the RCM reaction. This was consistent with the fact that only few examples of ring closure metathesis on vinyl or allyl halide substrates succeeded using the second generation Grubbs' catalyst.¹¹

Concerning 3-hydroxyoxaphosphinanes, we were aware that the Lewis basicity of both phosphoryl group and hydroxy group may result in catalyst deactivation.¹² We were pleased to see that functional oxaphosphinanes **9d** and **9f** were obtained, respectively in 70 and 50% as probably the result of a weak and/or reversible chelation. However, reactions failed with substituted precursors **6e** and **6g**. The course of the RCM reaction was monitored by ³¹P NMR to check the difference of behavior between the two diastereoisomers. Unfortunately, the reaction occurred nearly at the same rate resulting in no possible kinetic resolution. By the way, we managed to separate the diastereomers of **9d** by chromatography.

3. Conclusion

In conclusion, we have demonstrated a new way to synthesize diverse functionalized unsaturated phosphinates and phosphonates solving the problem of possible competitive side reactions. In parallel hydroxyphosphinate scaffolds represent a versatile starting material and could be of great interest for the synthesis of phosphosugar libraries. Perspective work will be devoted to control the chirality on α -hydroxyphosphonate or phosphinate precursors during the RCM¹³ or from the Pudovik reaction.¹⁴ These studies are underway and will be reported in due course.

4. Experimental section

4.1. General remarks

All reactions were carried under nitrogen atmosphere using Schlenk techniques. The solvents were dried using standard methods, distilled and stored under nitrogen. Reactions were monitored by 31 P NMR using DMSO- d_6 as internal references. Column chromatographies were performed on silica gel (Merck 60 AC.C 35–70 μ m).

³¹P, ¹H and ¹³C NMR spectra were recorded on a BRUKER AVANCE 250 and BRUKER AVANCE 400 spectrometers. MS and HRMS were recorded on a JEOL JMS DX-300 using NBA as matrix in FAB⁺ ionization mode. IR spectra were measured on a PERKIN-ELMER spectrum 1000.

4.2. Synthesis of unsaturated precursors

4.2.1. Diethyl vinylphosphonate (**1**). First step: synthesis of diethyl 2-chloroethylphosphonate. Triethyl phosphite (15.0 g, 90 mmol) and 1-bromo-2-chloroethane (51.8 g, 0.36 mol, 4 equiv) were heated at 140 °C for 24 h. Remaining starting materials were removed under vacuum. The residue was purified by column chromatography (AcOEt 100%) to give a colorless liquid (17.0 g, 94%); ³¹P NMR (101.25 MHz, CDCl₃): δ 26.7. ¹H NMR (250.13 MHz, CDCl₃): δ 4.05–3.93 (m, 4H, 2POCH₂), 3.78–3.66 (m, 2H, CH₂Cl), 2.25–2.15 (m, 2H, P-CH₂), 1.32 (t, ³J_{HH}=7.0 Hz, 6H, 2CH₃); ¹³C NMR (62.90 MHz, CDCl₃): δ 61.5 (d, ²J_{PC}=6.5 Hz, OCH₂), 34.8 (s, CH₂Cl), 2.9.9 (d, ¹J_{PC}=140.0 Hz, P-CH₂), 15.3 (d, ³J_{PC}=7.0 Hz, CH₃).

Second step: synthesis of diethyl vinylphosphonate (1). Diethyl 2-chloroethylphosphonate (10.0 g, 50.0 mmol) was slowly added to a cold solution of potassium hydroxide in ethanol (50 mmol,

75 mL). The reaction mixture was stirred during one hour then heated to reflux for 15 min. The solid was filtered off and washed with ethanol. Ethanol was removed under vacuum and the remaining oil was distilled under vacuum (Bp 93–97 °C/16 Torr). Yield: 6.19 g (85%).

³¹P NMR (101.25 MHz, CDCl₃): δ 17.9; ¹H NMR (250.13 MHz, CDCl₃): δ 6.31 (ddd, ³*J*_{HH}=18.7 Hz, ²*J*_{HH}=-1.9 Hz, ³*J*_{PH}=25.3 Hz, 1H, =C*H*₂), 6.14 (ddd, ³*J*_{HH}=12.8 Hz, ²*J*_{HH}=-1.9 Hz, ³*J*_{PH}=51.1 Hz, 1H, =C*H*₂), 6.07 (ddd, ³*J*_{HH}=12.8 Hz, ³*J*_{HH}=18.7 Hz, ²*J*_{PH}=21.9 Hz, 1H, PCH), 4.17-4.02 (m, 4H, 2C*H*₂), 1.29 (t, ³*J*_{HH}=7.6 Hz, 6H, 2C*H*₃); ¹³C NMR (62.90 MHz, CDCl₃): δ 135.0 (d, ²*J*_{PC}=1.9 Hz, C*H*₂), 126.0 (d, ¹*J*_{PC}=184.2 Hz, PCH), 61.7 (d, ²*J*_{PC}=5.6 Hz, OCH₂), 16.2 (s, CH₃).

4.2.2. Ethyl vinylphosphonochloridate (**2**). Diethyl vinylphosphonate (6.0 g, 36 mmol) in dry CH_2Cl_2 (100 mL) and oxalyl chloride (18.5 g, 146 mmol, 4.05 equiv) were stirred at room temperature for 24 h and refluxed for 1 h. Solvent and remaining oxalyl chloride were removed under vacuum at room temperature. Residue was purified by distillation (Bp 85 °C/15 Torr). Yield: 4.0 g (72%).

³¹P NMR (101.25 MHz, DMSO-*d*₆): δ 26.9; ¹³C NMR (62.90 MHz, DMSO-*d*₆): δ 135.6 (s, *CH*₂), 128.5 (d, ¹*J*_{PC}=169.3 Hz, *CH*), 62.9 (d, ²*J*_{PC}=7.8 Hz, *CH*₂), 15.1 (d, ³*J*_{PC}=7.1 Hz, *CH*₃).

4.2.3. Allyl ethyl vinylphosphonate (**3a**). Ethyl vinylphosphonochloridate **2** (1.68 g, 10.9 mmol) in dry Et₂O (10 mL) was added dropwise to a cold mixture of anhydrous allylic alcohol (1.13 g 19.4 mmol, 1.8 equiv) and triethylamine (2.0 g, 19.8 mmol, 1.8 equiv) in dry Et₂O (40 mL). The mixture was then stirred for 3 h at room temperature. The solid was removed by filtration and washed with Et₂O (3×10 mL). Solvents were removed under vacuum and the residue was purified by column chromatography (AcOEt 100%) Yield: 1.28 g (67%).

³¹P NMR (81.02 MHz, CDCl₃): δ 18.2; ¹H NMR (400.13 MHz, CDCl₃): δ 6.20 (ddd, ³*J*_{HH}=18.2 Hz, ²*J*_{HH}=-1.8 Hz, ³*J*_{PH}=25.1 Hz, 1H, =*CH*₂), 6.04 (³*J*_{HH}=12.9 Hz, ²*J*_{HH}=-1.8 Hz, ³*J*_{PH}=52.7 Hz, 1H, =*CH*₂), 5.99 (m, ³*J*_{HH}=5.8 Hz, ³*J*_{HH}=5.6 Hz, ³*J*_{HH}=10.4 Hz, ³*J*_{HH}=17.2 Hz, 1H, =*CH*₂), 5.98 (³*J*_{HH}=12.9 Hz, ³*J*_{HH}=16.4 Hz, ³*J*_{HH}=17.2 Hz, 1H, =*CH*₂), 5.98 (³*J*_{HH}=1.5 Hz, ⁴*J*_{HH}=10.4 Hz, ³*J*_{HH}=17.2 Hz, 1H, *CH*₂), 5.12 (m, ²*J*_{HH}=-1.5 Hz, ⁴*J*_{HH}=1.5 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=10.4 Hz, 1H, *CH*₂), 5.12 (m, ²*J*_{HH}=-1.5 Hz, ⁴*J*_{HH}=1.5 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=10.4 Hz, 1H, *CH*₂), 4.42 (m, ³*J*_{PH}=8.2 Hz, ²*J*_{HH}=-23.6 Hz, ⁴*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=5.8 Hz, 1H, *OCH*₂), 4.38 (m, ³*J*_{PH}=8.0 Hz, ²*J*_{HH}=-23.6 Hz, ⁴*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=5.6 Hz, 1H, *OCH*₂), 3.99 (qd, ³*J*_{HH}=7.1 Hz, ³*J*_{PH}=8.1 Hz, 2H, *OCH*₂), 1.22 (t, ³*J*_{HH}=7.1 Hz, 3H, *CH*₃); ¹³C NMR (62.90 MHz, *CDCl*₃): δ 136.0 (s, *CH*₂), 133.0 (d, ³*J*_{PC}=6.7 Hz, *CH*), 126.0 (d, ¹*J*_{PC}=184.0 Hz, *CH*), 118.3 (s, *CH*₂), 66.6 (d, ²*J*_{PC}=5.3 Hz, *CH*₂), 62.4 (d, ²*J*_{PC}=5.8 Hz, *CH*₂), 16.6 (d, ³*J*_{PC}=6.2 Hz, *CH*₃); FABMS (NBA, *m*/*z*, I, %): 177 [(M+H)⁺, 100%]MS FAB(+); HRMS *m*/*z* (MH⁺) 177.0693 (calcd for C₇H₁₃O₃P: 177.0680); IR (NaCl): *v* 3000, 2280, 1400, 1260, 1110, 1070, 1050, 980, 920, 750, 660 cm⁻¹.

4.2.4. Ethyl N-allyl-N-benzylvinylphosphonamidate (**3b**). A solution of ethyl vinylphosphonochloridate **2** (1.68 g, 10.9 mmol) in dry Et₂O (10 mL) was added dropwise to a cold mixture of anhydrous allylbenzylamine (1.6 g 10.9 mmol) and triethylamine (2.0 g, 19.8 mmol) in dry Et₂O (40 mL). The mixture was then stirred 44 h at room temperature. The solid was removed by filtration and washed with Et₂O (3×10 ml). Solvents were removed under vacuum and the residue was purified by column chromatography (AcOEt 100%). Yield 1.44 g (50%).

³¹P NMR (81.02 MHz, CDCl₃): δ 21.3; ¹H NMR (400.13 MHz, CDCl₃): δ 7.42–7.21 (m, 5H, *CH*_{Ar}), 6.18 (m, ³*J*_{HH}=18.6 Hz, ²*J*_{HH}=-2.0 Hz, ³*J*_{PH}=23.7 Hz, 1H, =CH₂), 6.14 (m, ³*J*_{HH}=12.7 Hz, ³*J*_{HH}=18.6 Hz, ²*J*_{PH}=22.3 Hz, 1H, *CH*), 6.04 (m, ²*J*_{HH}=-2.0 Hz, ³*J*_{HH}=12.7 Hz, ³*J*_{HH}=12.7 Hz, ³*J*_{HH}=12.7 Hz, ³*J*_{HH}=12.7 Hz, ³*J*_{HH}=12.7 Hz, ³*J*_{HH}=12.7 Hz, ³*J*_{HH}=10.2 Hz, ³*J*_{HH}=17.1 Hz, 1H, *CH*), 5.22–5.16 (m, ²*J*_{HH}=-1.3 Hz, ³*J*_{HH}=10.2 Hz, 1H, *CH*₂), 5.12 (dddd, ²*J*_{HH}=-1.3 Hz, ⁴*J*_{HH}=1.4 Hz,

⁴*J*_{HH}=1.3 Hz, ³*J*_{HH}=17.1 Hz, 1H, *CH*₂), 4.23 (dd, ²*J*_{HH}=-15.2 Hz, ²*J*_{PH}=9.2 Hz, 1H, N*CH*₂), 4.21 (dd, ²*J*_{HH}=-15.2 Hz, ²*J*_{PH}=9.2 Hz, 1H, N*CH*₂), 4.12 (qdd, ²*J*_{HH}=-10.1 Hz, ³*J*_{HH}=7.2 Hz, ³*J*_{PH}=7.2 Hz, 1H, O*CH*₂), 3.82 (qdd, ²*J*_{HH}=-10.1 Hz, ³*J*_{HH}=7.2 Hz, ³*J*_{PH}=7.4 Hz, 1H, O*CH*₂), 3.50 (m, ²*J*_{HH}=-9.7 Hz, ⁴*J*_{HH}=1.4 Hz, ⁴*J*_{HH}=-1.3 Hz, ³*J*_{HH}=6.4 Hz, ³*J*_{PH}=10.9 Hz, 1H, *CH*₂), 3.49 (m, ²*J*_{HH}=-9.7 Hz, ⁴*J*_{HH}=1.4 Hz, ⁴*J*_{HH}=7.2 Hz, 3H, *CH*₃); ¹³C NMR (100.61 MHz, *CDC*₁): δ 138.2 (d, ³*J*_{PC}=2.4 Hz, *CH*_{Ar}), 135.2 (d, ³*J*_{PC}=1.8 Hz, =*CH*), 135.0 (d, ¹*J*_{PC}=1.9 Hz, =*CH*₂), 128.3 and 128.6 (s, *CH*_{Ar}), 127.3 (s, *CH*), 126.0 (d, ¹*J*_{PC}=6.7 Hz, *CH*₃); FABMS (NBA, *m*/*z*, I, %): 266 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 266.1321 (calcd for C₁₄H₂₁NO₂P: 266.1310); IR (NaCl): *v* 3057, 2977, 2954, 1618, 1215, 1070, 1017, 722, 695, 670, 626, 598, 528, 500 cm⁻¹.

4.2.5. Diethyl allylphosphonate (**4a**). Triethylphosphite (20 mL, 120 mmol) and allyl bromide (11 mL g, 130 mmol) were heated at 140 °C for 4 h. Remaining allyl bromide was removed under vacuum. The product was purified by column chromatography (AcOEt 100%). Yield: 21.38 g (99%).

³¹P NMR (81.02 MHz, CDCl₃): δ 27.7; ¹H NMR (250.13 MHz, CDCl₃): δ 5.92–5.70 (m, 1H, =*CH*), 5.35–5.12 (m, 2H, =*CH*₂), 4.20–4.06 (m, 4H, *OCH*₂), 2.64 (m, ²*J*_{PH}=21.9 Hz, ³*J*_{HH}=7.4 Hz, ⁴*J*_{HH}=1.2 Hz, ⁴*J*_{HH}=1.2 Hz, 2H, *PCH*₂), 1.34 (t, ³*J*_{HH}=7.0 Hz, 6H, 2*CH*₃); ¹³C NMR (50.32 MHz, CDCl₃): δ 127.3 (d, ²*J*_{PC}=11.2 Hz, =*CH*), 119.5 (d, ³*J*_{PC}=14.5 Hz, =*CH*₂), 61.7 (d, ²*J*_{PC}=6.7 Hz, *OCH*₂), 31.5 (d, ¹*J*_{PC}=139.0 Hz, *PCH*₂), 16.2 (d, ³*J*_{PC}=6.0 Hz, *CH*₃).

4.2.6. Diethyl 2-chloroallylphosphonate (**4b**). Triethyl phosphite (20 mL, 120 mmol), 2-chloroallyl chloride (16.0 g, 140 mmol), and sodium bromide (14.8 g, 144 mmol) were heated at 140 °C for 18 h. Solid was filtered off and washed with AcOEt (3×10 mL). The product was purified by column chromatography (AcOEt/CH₂Cl₂ 1/1). Yield: 14.9 g (58%).

³¹P NMR (101.25 MHz, CDCl₃): δ 23.9; ¹H NMR (250.13 MHz, CDCl₃): δ 5.40–5.37 (m, =*CH*₂), 4.16 (qd, ${}^{3}J_{HH}$ =7.1 Hz, ${}^{3}J_{PH}$ =8.1 Hz, 4H, *OCH*₂), 2.94 (dd, 2H ${}^{2}J_{PH}$ =21.4 Hz, ${}^{4}J_{HH}$ =0.7 Hz, *PCH*₂), 1.35 (t, ${}^{3}J_{HH}$ =7.1 Hz, 6H, *CH*₃); ¹³C NMR (62.90 MHz, CDCl₃): δ 132.0 (d, ${}^{2}J_{PC}$ =11.4 Hz, =*CCl*), 117,0 (d, ${}^{3}J_{PC}$ =10.1 Hz, =*CH*₂), 62.7 (d, ${}^{2}J_{PC}$ =6.6 Hz, *OCH*₂), 37.5 (d, ${}^{1}J_{PC}$ =141.0 Hz, *PCH*₂), 16.5 (d, ${}^{3}J_{PC}$ =6.2 Hz, *CH*₃); FABMS (NBA, *m/z*, I, %): 213 [(M+H)⁺, 100%]; HRMS *m/z* (MH⁺) 213.0431 (calcd for C₇H₁₅ClO₃P: 213.0447); IR (NaCl): *ν* 3680, 3440, 3020, 1680, 1400, 1260, 1210, 1100, 750, 660 cm⁻¹.

4.2.7. *Ethyl allylphosphonochloridate* (**5***a*). Diethyl allylphosphonate (10.0 g, 56.0 mmol) in dry CH₂Cl₂ (40 mL) and oxalyl chloride (21.3 g, 168.0 mmol) were stirred at room temperature for 24 h and refluxed for 1 h. CH₂Cl₂ and remaining oxalyl chloride were removed under vacuum and the residue was used without further purification. Yield: 9.21 g (97%).

³¹P NMR (81.02 MHz, DMSO-*d*₆): δ 39.3; ¹H NMR (250.13 MHz, DMSO-*d*₆): δ 5.59 (m, ³*J*_{PH}=9.1 Hz, ³*J*_{HH}=12.0 Hz, ³*J*_{HH}=13.3 Hz, ³*J*_{HH}=7. 3 Hz, 1H, =*CH*), 5.16 (m, ⁴*J*_{PH}=5.5 Hz, ²*J*_{JHH}=-1.3 Hz, ⁴*J*_{HH}=1.2 Hz, ³*J*_{HH}=12.4 Hz, 1H, =*CH*₂), 5.12 (m, ⁴*J*_{PH}=4.8 Hz, ²*J*_{HH}=-1.2 Hz, ⁴*J*_{HH}=1.1 Hz, ³*J*_{HH}=13.3 Hz, 1H, =*CH*₂), 4.20–3.96 (m, 2H, OCH₂), 2.92 (m, ²*J*_{PH}=22.4 Hz, ⁴*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.2 Hz, ³*J*_{HH}=7.3 Hz, 1H, PCH₂), 1.16 (t, ³*J*_{HH}=7.1 Hz, 3H_H=1.1 Hz, ⁴*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.2 Hz, ³*J*_{HH}=7.3 Hz, 1H, PCH₂), 1.16 (t, ³*J*_{HH}=7.1 Hz, 3H, CH₃); ¹³C NMR (50.32 MHz, DMSO-*d*₆): δ 126.3 (d, ²*J*_{PC}=8.6 Hz, OCH₂), 39.0 (d, ¹*J*_{PC}=121.9 Hz, PCH₂), 16.0 (d, ³*J*_{PC}=7.2 Hz, CH₃).

4.2.8. Ethyl 2-chloroallylphosphonochloridate (**5b**). Diethyl 2-chloroallylphosphonate (9.66 g, 45 mmol) in dry CH_2Cl_2 (80 mL)

and oxalyl chloride (23.7 g, 186 mmol) were stirred at room temperature for 10 h and refluxed for 24 h. CH_2Cl_2 and remaining oxalyl chloride were removed under vacuum. Product was used without further purification. Yield: 8.86 g (97%).

³¹P NMR (101.25 MHz, DMSO-*d*₆): δ 33.8; ¹H NMR (250.13 MHz, DMSO-*d*₆): δ 4.92–5.14 (m, 2H, =*C*H₂), 3.70–3.91 (m, 2H, *OC*H₂), 2.84–2.88 (m, 2H, *PC*H₂), 0.94 (t, ³*J*_{HH}=7.1 Hz, 3H, *C*H₃); ¹³C NMR (62.90 MHz, DMSO-*d*₆): δ 130.0 (d, ²*J*_{PC}=13.0 Hz, *CCI*), 118.9 (d, ³*J*_{PC}=12.3 Hz, =*C*H₂), 64.0 (d, ²*J*_{PC}=8.4 Hz, *OC*H₂), 44.0 (d, ¹*J*_{PC}=125.7 Hz, *PC*H₂), 15.8 (d, ³*J*_{PC}=6.9 Hz, *CH*₃).

4.2.9. Allyl ethyl allylphosphonate (**6a**). A solution of ethyl allylphosphonochloridate (1.84 g, 10.9 mmol) in dry diethylether (10 mL) was added dropwise to a cold mixture of anhydrous allylic alcohol (1.13 g, 19.4 mmol) and triethylamine (2.0 g, 19.8 mmol) in dry diethylether (40 mL). The mixture was then stirred for 3 h at room temperature. The solid was removed by filtration and washed with ether (3×10 ml). Solvents were removed under vacuum and the residue was purified by column chromatography (AcOEt 100%). Yield: 1.28 g (67%).

³¹P NMR (81.02 MHz, CDCl₃): δ 28.0; ¹H NMR (250.13 MHz, CDCl₃): δ 6.02–5.60 (m, 2H, 2 =*CH*), 5.41–5.07 (m, 4H, 2 =*CH*₂), 4.53–4.44 (m, 2H, OCH₂), 4.15–3.98 (m, 2H, OCH₂), 2.91–2.75 (m, ²J_{PH}=21.3 Hz, ⁴J_{HH}=1.1 Hz, ⁴J_{HH}=1.2 Hz, ³J_{HH}=7.3 Hz, 2H, PCH₂), 1.16 (t, ³J_{HH}=7.1 Hz, 3H, CH₃); ¹³C NMR (50.32 MHz, CDCl₃): δ 135.4 (d, ³J_{PC}=6.7 Hz, =*CH*), 127.5 (d, ²J_{PC}=13.2 Hz, =*CH*), 123.2 (d, ³J_{PC}=16.4 Hz, =*CH*₂), 118.3 (s, =*CH*₂), 66.6 (d, ²J_{PC}=5.3 Hz, OCH₂), 62.4 (d, ²J_{PC}=5.8 Hz, OCH₂), 39.2 (d, ¹J_{PC}=126.6 Hz, PCH₂), 16.6 (d, ³J_{PC}=6.2 Hz, CH₃); FABMS (NBA, *m*/*z*, I, %): 219 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 219.1165 (calcd for C₁₀H₂₀O₃P: 219.1150); IR (NaCl): *ν* 3330, 3000, 2280, 1690, 1400, 1210, 1110, 1070, 1050, 980, 920, 750, 660 cm⁻¹.

4.2.10. Allyl ethyl 2-chloroallylphosphonate (**6b**). A solution of ethyl 2-chloroallylphosphonochloridate (1.13 g, 10.9 mmol) in dry Et₂O (10 mL) was added dropwise to a cold mixture of anhydrous allyl alcohol (1.13 g 19.4 mmol) and triethylamine (2.0 g, 19.8 mmol) in dry Et₂O (40 mL). The mixture was then stirred for 3 h at room temperature. The solid was removed by filtration and washed with Et₂O (3×10 mL). Solvents were removed under vacuum and the residue was purified by column chromatography (AcOEt 100%). Yield 1.28 g (67%).

³¹P NMR (81.02 MHz, CDCl₃): δ 23.8; ¹H NMR (250.13 MHz, CDCl₃): δ 6.00–5.83 (m,1H =*CH*), 5.43–5.21 (m, 4H, =*CH*₂), 4.59–4.52 (m, *OCH*₂), 4.20–4.02 (m, *OCH*₂), 2.94 (dd, ²*J*_{PH}=21.4 Hz, ⁴*J*_{HH}=0.7 Hz, 2H, *PCH*₂), 1.32 (t, ³*J*_{HH}=7.1 Hz, 3H, *CH*₃); ¹³C NMR (62.90 MHz, CDCl₃): δ 132.6 (d, ²*J*_{PC}=10.8 Hz, *CCl*), 131.7 (d, ³*J*_{PC}=6.2 Hz, =*CH*), 117.8 (s, =*CH*₂), 116.8 (d, ³*J*_{PC}=10.0 Hz, =*CH*₂), 66.5 (d, ²*J*_{PC}=5.8 Hz, *OCH*₂), 62.3 (d, ²*J*_{PC}=6.8 Hz, *OCH*₂), 37.1 (d, ¹*J*_{PC}=141.0 Hz, *PCH*₂), 16.2 (d, ³*J*_{PC}=6.2 Hz, *CH*₃); FABMS (NBA, *m*/*z*, I, %): 225 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 225.0435 (calcd for C₈H₁₅ClO₃P: 225.0447); IR (NaCl): *ν* 3680, 3440, 3020, 1680, 1400, 1260, 1210, 1100 cm⁻¹.

4.2.11. Ethyl N-allyl-N-benzyl-allylphosphonamidate (**6c**). A solution of ethyl allylphosphonochloridate (1.0 g, 5.9 mmol) in dry diethylether (10 mL) was added dropwise to a cold mixture of anhydrous allylbenzylamine (0.80 g, 5.45 mmol) and triethylamine (1.0 g, 9.9 mmol) in dry diethylether (40 mL). The mixture was then stirred for 48 h at room temperature. The solid was removed by filtration and washed with ether (3×10 ml). Solvents were removed under vacuum and the residue was purified by column chromatography (AcOEt 100%). Yield 0.785 g (46%).

³¹P NMR (81.02 MHz, CDCl₃): δ 27.1; ¹H NMR (400.13 MHz, CDCl₃): δ 7.47–7.23 (m, 5H, CH_{Ar}), 5.84 (m, ³J_{HH}=7.5 Hz, ³J_{HH}=7.4 Hz, ³J_{HH}=9.4 Hz, ³J_{HH}=17.7 Hz, ³J_{PH}=6.0 Hz, 1H, =CH), 5.72 (tdd,

 ${}^{3}J_{HH}$ =7.1 Hz, ${}^{3}J_{HH}$ =5.9 Hz, ${}^{3}J_{HH}$ =10.3 Hz, ${}^{3}J_{HH}$ =17.0 Hz, 1H, =*CH*), 5.20 $(m, {}^{2}J_{HH}=-1.7 \text{ Hz}, {}^{4}J_{HH}=1.3 \text{ Hz}, {}^{4}J_{HH}=1.4 \text{ Hz}, {}^{3}J_{HH}=9.4 \text{ Hz}, {}^{4}J_{PH} \text{ un-}$ determined, 1H, =*CH*₂), 5.18 (m, ${}^{2}J_{HH}$ =-1.7 Hz, ${}^{4}J_{HH}$ =1.2 Hz, ${}^{4}J_{HH}$ =1.4 Hz, ${}^{3}J_{HH}$ =17.7 Hz, ${}^{4}J_{PH}$ undetermined, 1H, =*CH*₂), 5.17 (m, ${}^{2}J_{\text{HH}}$ =-1.5 Hz, ${}^{4}J_{\text{HH}}$ =1.2 Hz, ${}^{4}J_{\text{HH}}$ =1.2 Hz, ${}^{3}J_{\text{HH}}$ =10.3 Hz, 1H, =*CH*₂), 5.12 (m, ${}^{2}J_{HH}$ =-1.5 Hz, ${}^{4}J_{HH}$ =1.4 Hz, ${}^{4}J_{HH}$ =1.4 Hz, ${}^{3}J_{HH}$ =17.0 Hz, 1H, =*CH*₂), 4.25 (dd, ${}^{2}J_{HH}$ =-15.0 Hz, ${}^{3}J_{PH}$ =8.8 Hz, 1H, *NCH*₂*Ph*), 4.16 (dd, ${}^{2}J_{HH}$ =-15.0 Hz, ${}^{3}J_{PH}$ =9.4 Hz, 1H, *NCH*₂*Ph*), 4.12 (qdd, (uu, $j_{HH}=-15.0$ Hz, $j_{PH}=9.4$ Hz, 1H, $NCH_2(H)$, 4.12 (quu, ${}^{2}J_{HH}=-10.0$ Hz, ${}^{3}J_{HH}=7.0$ Hz, ${}^{3}J_{PH}=7.0$ Hz, 1H, OCH_2), 3.88 (qdd, ${}^{2}J_{HH}=-10.0$ Hz, ${}^{3}J_{HH}=7.2$ Hz, ${}^{3}J_{PH}=7.2$ Hz, 1H, OCH_2), 3.50 (m, ${}^{2}J_{HH}=-17.2$ Hz, ${}^{4}J_{HH}=1.2$ Hz, ${}^{4}J_{HH}=1.4$ Hz, ${}^{3}J_{HH}=7.1$ Hz, ${}^{3}J_{PH}=10.4$ Hz, 1H, NCH_2), 3.49 (m, ${}^{2}J_{HH}=-17.2$ Hz, ${}^{4}J_{HH}=1.2$ Hz, ${}^{4}J_{HH}=-1.2$ Hz, ${}^{4}J_{HH}=-1.2$ Hz, ${}^{4}J_{HH}=-1.2$ Hz, ${}^{4}J_{HH}=-1.2$ Hz, ${}^{4}J_{HH}=-1.4$ Hz, ${}^{3}J_{HH}=5.9$ Hz, ${}^{3}J_{PH}=10.4$ Hz, 1H, NCH_2), 2.67 3H, CH₃); ¹³C NMR (100.61 MHz, CDCl₃): δ 138.2 (d, ³J_{PC}=2.4 Hz, C_{Ar}), 135.2 (d, ${}^{3}J_{PC}=1.8$ Hz, CH=), 128.4 and 128.6 (s, CH_{Ar}), 128.4 (d, $^{2}J_{PC}$ =10.4 Hz, =*CH*), 127.3 (s, *CH*_{Ar}), 119.6 (d, $^{3}J_{PC}$ =14.1 Hz, =*CH*₂), 118.3 (s, =*CH*₂), 59.9 (d, ${}^{2}J_{PC}$ =6.7 Hz, OCH₂), 48.1 (d, ${}^{2}J_{PC}$ =4.3 Hz, NCH₂), 47.1 (d, ²*J*_{PC}=4.3 Hz, NCH₂), 33.5 (d, ¹*J*_{PC}=128.7 Hz, PCH₂), 16.2 (d, ${}^{3}J_{PC}=6.7$ Hz, CH_{3}); FABMS (NBA, m/z, I, %): 280 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 280.1474 (calcd for C₁₅H₂₃NO₂P: 280.1466); IR (NaCl): v 3060, 2978, 2960, 1600, 1222, 1076, 1025, 723, 690, 671, 540, 500 cm^{-1} .

4.2.12. Allyl phenylphosphinate (**7**). Pyridine (9.5 g, 120 mmol) was added dropwise to a mixture of allyl chloroformate (14.5 g, 120 mmol) and phenylphosphinic acid (16.8 g, 120 mmol) in CH₂Cl₂ (250 mL). Once gas evolution has stopped, the reaction mixture was heated to reflux for 15 min, and then cooled to room temperature and 100 mL of HCl 0.1 N were added and stirred for 30 min. Organic layer was extracted twice with 70 mL of water, dried with Na₂SO₄, filtered and solvent was removed under vacuum. The remaining oil is distilled under vacuum (*T*=121 °C, 1 mmHg). Yield 14.12 g (65%).

³¹P NMR (161.97 MHz, CDCl₃): δ 25.1; ¹H NMR (400.13 MHz, CDCl₃): δ 7.60 (d, ¹*J*_{PH}=564.9 Hz, 1H, *PH*), 7.79–7.73 (m, 2H, *CH*_{Ar}), 7.59–7.55 (m, 1H, *CH*_{Ar}), 7.50–7.47 (m, 2H, *CH*_{Ar}), 5.93 (m, ³*J*_{HH}=5.6 Hz, ³*J*_{HH}=5.6 Hz, ³*J*_{HH}=10.3 Hz, ³*J*_{HH}=17.2 Hz, 1H, =*CH*), 5.36 (m, ²*J*_{HH}=-1.6 Hz, ⁴*J*_{HH}=1.5 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=17.2 Hz, 1H, =*CH*), 5.24 (m, ²*J*_{HH}=-1.6 Hz, ⁴*J*_{HH}=8.7 Hz, ²*J*_{HH}=-1.3 6 Hz, ³*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=5.6 Hz, 1H, =*CH*₂), 4.59 (m, ³*J*_{PH}=8.7 Hz, ²*J*_{HH}=-13.6 Hz, ⁴*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=-1.6 Hz, ⁴*J*_{HH}=1.1 Hz, ⁴*J*_{HH}=5.6 Hz, 1H, *OCH*₂); ¹³C NMR (100.61 MHz, CDCl₃): δ 133.17 (d, ⁴*J*_{PC}=3.1 Hz, *CH*_{Ar}), 132.33 (d, ²*J*_{PC}=6.7 Hz, *CH*_{Ar}), 130.8 (d, ³*J*_{PC}=11.9 Hz, *CH*_{Ar}), 129.6 (d, ¹*J*_{PC}=132.4 Hz, *C*_{Ar}), 128.7 (d, ³*J*_{PC}=14.3 Hz, =*CH*), 118.6 (s, =*CH*₂), 66.1 (d, ²*J*_{PC}=6.3 Hz, *OCH*₂).

4.3. General procedure for Pudovik reaction compounds 6d-g

In a schlenck tube under N₂, potassium fluoride on alumina (5– 10% w/w) was added to a mixture of 1 equiv of allyl phenylphosphinate and 1 equiv of α , β -unsaturated carbonyl compound until no liquid phase remained. The mixture was left for 30 min at room temperature and then extracted with CH₂Cl₂. The solid phase was washed with 3×10 mL of CH₂Cl₂. Solvent was removed under reduced pressure and the resulting oil was purified through column chromatography on silica gel.

4.3.1. Allyl 1-hydroxybut-2-enylphenylphosphinate (**6d**). α , β -un-saturated carbonyl compound: crotonaldehyde (0.384 mg). Chromatography eluent: AcOEt 100%. Yield 0.985 g (71%).

³¹P NMR (161.97 MHz, CDCl₃): δ 39.3 (50%), 40.0 (50%); ¹H NMR (400.13 MHz, CDCl₃): δ 7.85–7.75 (m, 2H, *CH*_{Ar}), 7.60–7.55

(m, 1H, *CH*_{Ar}), 7.50–7.46 (m, 2H, *CH*_{Ar}), 5.96 (m, ³*J*_{HH}=7.2 Hz, ³*J*_{HH}=6.6 Hz, ³*J*_{HH}=10.4 Hz, ³*J*_{HH}=17.2 Hz, 1H, =*CH*), 5.75 (m, 1H, =*CH*-*CH*₃), 5.74 (m, 1H, =*CH*-*CH*₃), 5.62 (m, ³*J*_{PH}=4.6 Hz, ³*J*_{HH}=16.8 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=5.5 Hz, 1H, =*CH*), 5.52 (m, ³*J*_{PH}=4.56 Hz, ³*J*_{HH}=15.03 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=4.8 Hz, 1H, =*CH*), 5.36 (m, ²*J*_{HH}=-2.8 Hz, ⁴*J*_{HH}=2.4 Hz, ⁴*J*_{HH}=1.4 Hz, ³*J*_{HH}=17.20 Hz, H, =*CH*₂), 5.24 (m, ²*J*_{HH}=-2.8 Hz, ⁴*J*_{HH}=2.4 Hz, ⁴*J*_{HH}=1.4 Hz, ³*J*_{HH}=10.4 Hz, 1H, =*CH*₂), 4.63 (m, ²*J*_{PH}=9.6 Hz, ⁴*J*_{HH}=13.0 Hz, ³*J*_{HH}=10.4 Hz, ⁴*J*_{HH}=1.6 Hz, 1H, *CHOH*), 4.60 (m, ²*J*_{HH}=-12.9 Hz, ⁴*J*_{HH}=1.3 Hz, ⁴*J*_{HH}=1.4 Hz, ³*J*_{HH}=6.6 Hz, 1H, *OCH*₂), 4.54 (m, ³*J*_{HH}=0.4 Hz, ⁴*J*_{HH}=2.4 Hz, ⁴*J*_{HH}=2.4 Hz, ³*J*_{HH}=7.2 Hz, 1H, *CHOH*), 4.47 (m, ²*J*_{PH}=9.6 Hz, ²*J*_{HH}=-12.9 Hz, ³*J*_{HH}=5.5 Hz, ⁵*J*_{HH}=1.3 Hz, ¹*H*_H=0.6 Hz, 3H, *CH*₃), 1.69 (m, ⁵*J*_{PH}=5.0 Hz, ⁵*J*_{HH}=1.5 Hz, ³*J*_{HH}=1.5 Hz, ³*J*_{HH}=6.58 Hz, 3H, *CH*₃); ¹³C NMR (100.61 MHz, CDCl₃): δ 133.1 (d, ³*J*_{PC}=2.4 Hz, *=CH*), 133.0 (d, ³*J*_{PC}=1.8 Hz, *=CH*), 132.7 (d, ²*J*_{PC}=9.2 Hz, *CH*_{Ar}), 122.6 (d, ⁴*J*_{PC}=3.7 Hz, *CH*_{Ar}), 132.5 (d, ³*J*_{PC}=12.2 Hz, *=CH*-*CH*₃), 129.6 (d, ³*J*_{PC}=12.2 Hz, *CH*-*CH*₃), 128.3 (d, ³*J*_{PC}=12.3 Hz, *CH*_{Ar}), 125.3 (d, ²*J*_{PC}=12.2 Hz, *=CH*-*CH*₃), 129.6 (d, ³*J*_{PC}=12.2 Hz, *CH*-*CH*₃), 128.3 (d, ³*J*_{PC}=12.3 Hz, *CH*_{Ar}), 125.3 (d, ²*J*_{PC}=2.4 Hz, *=CH*), 117.7 (s, *=CH*₂), 117.7 (s, *=CH*₂), 71.6 (d, ¹*J*_{PC}=12.0 Hz, *CH*_{Ar}), 125.4 (d, ²*J*_{PC}=1.8 Hz, *=CH*), 125.3 (d, ²*J*_{PC}=2.4 Hz, *CH*₃), 17.9 (d, ⁴*J*_{PC}=1.8 Hz, *CH*₃); FABMS (NBA, *m*/*z*, 1,%): 253 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 253.0991 (calcd for C₁₃H₁₈O₃P: 253.0993); IR (NaCl): *v* 3266, 2900, 1722, 1649, 1592, 1439, 1424, 1377, 1214, 1121, 1092, 1050, 925, 845, 820, 748, 695, 5

4.3.2. Allyl 1-hydroxy-2-methylprop-2-enylphenyl-phosphinate (**6e**). α ,β-unsaturated carbonyl compound: methylacroleine (0.384 g). Chromatography eluent: AcOEt 100%. Yield 1.00 g (73%).

³¹P NMR (161.97 MHz, CDCl₃): δ 39.5 (51%), 40.0 (49%); ¹H NMR (400.13 MHz, CDCl₃): δ 7.85–7.75 (m, 2H, CH_{Ar}), 7.60–7.55 (m, 1H, CH_{Ar}), 7.50–7.46 (m, 2H, CH_{Ar}), 5.95 (m, ${}^{3}J_{HH}$ =7.1 Hz, ${}^{3}J_{HH}$ =2.6 Hz, ${}^{3}J_{\text{HH}}$ =10.4 Hz, ${}^{3}J_{\text{HH}}$ =17.0 Hz, 1H, =*CH*), 5.36 (m, ${}^{2}J_{\text{HH}}$ =-1.8 Hz, ${}^{4}J_{\text{HH}}=1.5 \text{ Hz}, {}^{4}J_{\text{HH}}=1.6 \text{ Hz}, {}^{3}J_{\text{HH}}=17.0 \text{ Hz}, \text{ H}, =CH_{2}), 5.34 \text{ (m,}$ ${}^{2}J_{\text{HH}} = -1.8 \text{ Hz}, {}^{4}J_{\text{HH}} = 1.5 \text{ Hz}, {}^{4}J_{\text{HH}} = 1.6 \text{ Hz}, {}^{3}J_{\text{HH}} = 17.0 \text{ Hz}, \text{ H}, =CH_{2}),$ 5.25 (m, ${}^{2}J_{HH}$ =-1.8 Hz, ${}^{4}J_{HH}$ =1.5 Hz, ${}^{4}J_{HH}$ =2.6 Hz, ${}^{3}J_{HH}$ =10.4 Hz, 1H, = CH_2), 5.23 (m, ² J_{HH} =-1.8 Hz, ⁴ J_{HH} =1.5 Hz, ⁴ J_{HH} =2.6 Hz, ${}^{3}J_{\text{HH}}$ =10.4 Hz, 1H, =*C*H₂), 4.96 (m, ${}^{4}J_{\text{PH}}$ =5.7 Hz, ${}^{4}J_{\text{HH}}$ =1.2 Hz, ${}^{2}J_{\text{HH}}$ =-2.9 Hz, ${}^{4}J_{\text{HH}}$ =0.8 Hz, 1H, =CH₂), 4.93 (m, ${}^{4}J_{\text{PH}}$ =4.2 Hz, ${}^{4}J_{\text{HH}}$ =1.2 Hz, ${}^{2}J_{\text{HH}}$ =-2.8 Hz, ${}^{4}J_{\text{HH}}$ =1.5 Hz, 1H, =*CH*₂), 4.92 (m, ${}^{4}J_{PH}$ =5.7 Hz, ${}^{4}J_{HH}$ =1.2 Hz, ${}^{2}J_{HH}$ =-2.8 Hz, ${}^{4}J_{HH}$ =0.8 Hz, 1H, =*CH*₂), 4.90 (m, ${}^{4}J_{PH}$ =4.2 Hz, ${}^{4}J_{HH}$ =1.2 Hz, ${}^{2}J_{HH}$ =-2.8 Hz, ${}^{4}J_{HH}$ =1.5 Hz, 1H, = CH_2), 4.63 (m, ² J_{HH} =-12.4 Hz, ⁴ J_{HH} =1.5 Hz, ⁴ J_{HH} =1.6 Hz, ${}^{3}J_{HH}$ =7.1 Hz, 1H, OCH₂), 4.60 (m, ${}^{3}J_{PH}$ =undetermined, ${}^{2}J_{HH}$ =-12.4 Hz, ${}^{4}J_{HH}$ =1.5 Hz, ${}^{4}J_{HH}$ =1.6 Hz, ${}^{3}J_{HH}$ =7.1 Hz, 1H, OCH₂), 4.48 (m, ${}^{3}J_{PH}$ =undetermined, ${}^{2}J_{HH}$ =-12.4 Hz, ${}^{4}J_{HH}$ =1.5 Hz, 4.48 (III, $_{JPH}$ =undetermined, $_{JHH}$ = 12.4 Hz, $_{JHH}$ = 1.5 Hz, $_{J_{HH}}^{4}$ =1.1 Hz, $_{J_{HH}}^{3}$ =2.6 Hz, 1H, OCH₂), 4.46 (m, $_{J_{PH}}^{3}$ =undetermined, $_{J_{HH}}^{2}$ =-12.4 Hz, $_{J_{HH}}^{4}$ =1.5 Hz, $_{J_{HH}}^{4}$ =1.1 Hz, $_{J_{HH}}^{3}$ =2.6 Hz, 1H, OCH₂), 4.57 (m, $_{J_{PH}}^{2}$ =9.3 Hz, $_{J_{HH}}^{4}$ =1.5 Hz, $_{J_{HH}}^{4}$ =0.8 Hz, 1H, PCH), 1.85 (m, $_{J_{PH}}^{4}$ =2.7 Hz, $_{J_{HH}}^{4}$ =1.2 Hz, $_{J_{HH}}^{4}$ =1.2 Hz, 3H, CH₃), 1.76 (m, $_{J_{PH}}^{4}$ =2.7 Hz, $_{J_{HH}}^{4}$ =1.2 Hz, $_{J_{HH}}^{4}$ =1.2 Hz, 3H, CH₃); 1³C NMR (100.61 MHz, CDCl₃): $_{\delta}$ 140.6 (d, $_{J_{PC}}^{2}$ =5.1 Hz, 20 (d, $_{J_{H}}^{3}$), 6.6 Hz $^{2}J_{PC}$ =5.1 Hz, =*C*), 133.0 (d, $^{3}J_{PC}$ =6.6 Hz, =*C*H), 132.9 (d, $^{3}J_{PC}$ =6.6 Hz, =CH), 132.7 (d, ${}^{2}J_{PC}$ =9.5 Hz, CH_{Ar}), 132.7 (d, ${}^{4}J_{PC}$ =2.2 Hz, CH_{Ar}), 128.3 (d, ${}^{3}J_{PC}$ =12.4 Hz, CH_{Ar}), 128.2 (d, ${}^{3}J_{PC}$ =12.4 Hz, CH_{Ar}), 127.7 (d, $^{1}J_{PC}$ =122.9 Hz, C_{Ar}), 127.5 (d, $^{1}J_{PC}$ =122.9 Hz, C_{Ar}), 118.0 (s, = CH_{2}), 114.4 (d, ${}^{3}J_{PC}$ =10.2 Hz, =*CH*₂), 114.3 (d, ${}^{3}J_{PC}$ =9.5 Hz, =*CH*₂), 74.6 (d, $J_{PC}=109.0$ Hz, PCH), 74.5 (d, $J_{PC}=109.8$ Hz, PCH), 65.9 (d, ${}^{3}J_{PC}$ =7.3 Hz, OCH₂), 65.8 (d, ${}^{3}J_{PC}$ =6.6 Hz, OCH₂), 20.1 (d, ${}^{3}J_{PC}$ =2.2 Hz, CH₃), 19.9 (d, ${}^{3}J_{PC}=2.2$ Hz, CH₃); MS FAB⁺ (NBA) m/z (%): 253 $(M+H)^+$ (100) MS HR⁺ (NBA) C₁₃H₁₈O₃P: 253.0993 found: 253.1025; IR (NaCl): v 3280, 3060-2800, 1695, 1592, 1450, 1224, 1130, 1050, 925, 760, 682 cm⁻¹.

4.3.3. Allyl 1-hydroxy-1-methylprop-2-enylphenyl-phosphinate (**6f**). α , β -unsaturated carbonyl compound: methylvinylketone (0.384 g). Chromatography eluent: AcOEt 100%, Yield 0.510 g (39%).

 31 P NMR (161.97 MHz, CDCl₃): δ 41.8 (50%, dia 1), 41.9 (50%, dia 2); ¹H NMR (400.13 MHz, CDCl₃): δ 7.92–7.75 (m, 2H, CH_{Ar}), 7.64– 7.50 (m, 1H, CH_{Ar}), 7.53–7.42 (m, 2H, CH_{Ar}), 6.10–5.89 (m, 2H, =CH), 5.40-5.19 (m, 4H, =CH₂), 4.72-4.66 (m, 2H, OCH₂), 4.42-4.36 (m, 2H, OCH_2), 3.80 (sl, OH), 3.70 (sl, OH), 1.56 (d, ${}^{3}J_{PH}$ =14.8 Hz, 3H, CH_3), 1.49 (d, ${}^{3}J_{PH}$ =15.0 Hz, 3H, CH_3); ${}^{13}C$ NMR (100.61 MHz, CDCl₃): δ 137.5 (d, ²*J*_{PC}=0.9 Hz, =*CH*), 138.1 (d, ²*J*_{PC}=1.5 Hz, =*CH*), 133.0 (d, J_{PC}=3.1 Hz, =*CH*), 133.1 (d, J_{PC}=2.4 Hz, =*CH*), 132.6 (d, J_{PC}=9.1 Hz, CH_{Ar}), 132.6 (d, J_{PC} =3.7 Hz, CH_{Ar}), 128.2 (d, ${}^{3}J_{PC}$ =12.3 Hz, CH_{Ar}), 128.1 (d, ${}^{3}J_{PC}$ =11.0 Hz, *CH*_{Ar}), 127.4 (d, ${}^{1}J_{PC}$ =119.5 Hz, *C*_{Ar}), 127.1 (d, $^{1}J_{PC}$ =120.1 Hz, C_{Ar}), 117.8 (s, = CH_{2}), 117.7 (s, = CH_{2}), 116.0 (d, ${}^{3}J_{PC}=9.2$ Hz, $=CH_{2}$), 115.5 (d, ${}^{3}J_{PC}=9.2$ Hz, $=CH_{2}$), 74.5 (d, ${}^{1}J_{PC}$ =112.4 Hz, PC), 74.3 (d, ${}^{1}J_{PC}$ =114.6 Hz, PC), 66.1 (d, ${}^{3}J_{PC}$ =7.1 Hz, OCH₂), 65.9 (d, ³J_{PC}=7.4 Hz, OCH₂), 22.9 (d, ²J_{PC}=2.6 Hz, CH₃), 22.6 (d, ${}^{2}J_{PC}=2.6$ Hz, CH_{3}); FABMS (NBA, m/z, I, %): 253 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 253.0997 (calcd for C₁₃H₁₈O₃P: 253.0993); IR (NaCl): v 3239, 1590, 1646, 1438, 1364, 1200, 1119, 1020, 855, 832, 744, 680, 552 cm⁻¹.

4.3.4. Allyl 2-bromo-1-hydroxy-3-phenylprop-2-enylphenylphosphinate (**6g**). α , β -unsaturated carbonyl compound: 2-bromocinnamaldehyde (1.16 g). Chromatography eluent: AcOEt/CH₂Cl₂ 4/6. Yield 0.260 g and 0.280 g (39% for both stereoisomers).

4.3.4.1. *First diastereomer*. ³¹P NMR (161.97 MHz, CDCl₃): δ 39.7; ¹H NMR (400.13 MHz, CDCl₃): δ 7.89–7.83 (m, 2H, CH_{Ar}), 7.37–7.28 (m, 5H, CH_{Ar}), 7.61–7.56 (m, 1H, CH_{Ar}), 7.49–7.44 (m, 2H, CH_{Ar}), 6.92 (dd, ${}^{4}J_{PH}$ =4.8 Hz, ${}^{3}J_{HH}$ =0.4 Hz, 1H, =*CHPh*), 6.00 (m, ${}^{3}J_{HH}$ =5.3 Hz, ${}^{3}J_{\text{HH}}$ =5.4 Hz, ${}^{3}J_{\text{HH}}$ =10.5 Hz, ${}^{3}J_{\text{HH}}$ =17.1 Hz, 1H, =*CH*), 5.45 (m, ${}^{2}J_{\text{HH}} = -1.4 \text{ Hz}, {}^{4}J_{\text{HH}} = 1.5 \text{ Hz}, {}^{4}J_{\text{HH}} = 1.5 \text{ Hz}, {}^{3}J_{\text{HH}} = 17.1 \text{ Hz}, 1\text{ H}, =CH_{2}$), 5.27 (m, ${}^{2}J_{HH}$ =-1.4 Hz, ${}^{4}J_{HH}$ =1.4 Hz, ${}^{4}J_{HH}$ =1.4 Hz, ${}^{3}J_{HH}$ =10.5 Hz, 1H, =*CH*₂), 5.02 (dd, ²*J*_{PH}=12.1 Hz, ³*J*_{HH}=1.1 Hz, 1H, *CHOH*), 4.74 (m, ${}^{3}J_{PH}$ =6.9 Hz, ${}^{2}J_{HH}$ =-12.9 Hz, ${}^{4}J_{HH}$ =1.5 Hz, ${}^{4}J_{HH}$ =1.4 Hz, ${}^{3}J_{HH}$ =5.3 Hz, H, OCH₂), 4.61 (m, ${}^{3}J_{PH}=7.2$ Hz, ${}^{2}J_{HH}=-12.9$ Hz, ${}^{4}J_{HH}=1.5$ Hz, ${}^{4}J_{HH}$ =1.4 Hz, ${}^{3}J_{HH}$ =5.3 Hz, 1H, OCH₂); ${}^{13}C$ NMR (100.61 MHz, CDCl₃): δ 135.1 (d, ${}^{4}J_{PC}$ =3.1 Hz, CH_{Ar}), 133.1 (d, ${}^{4}J_{PC}$ =3.1 Hz, CH_{Ar}), 133.0 (d, ${}^{6}J_{PC}=9.8$ Hz, CH_{Ar}), 132.7 (d, ${}^{3}J_{PC}=6.7$ Hz, =CH), 131.1 (d, ${}^{2}J_{PC}=9.8$ Hz, CH_{Ar}), 128.9 (d, ${}^{3}J_{PC}=2.4$ Hz, =CH), 128.3 (d, ³*J*_{PC}=12.9 Hz, *CH*_{Ar}), 128.0 (d, ⁵*J*_{PC}=1.8 Hz, *CH*_{Ar}), 128.0 (s, *CH*_{Ar}), 126.4 (d, ${}^{1}J_{PC}$ =127.4 Hz, C), 120.0 (s, CBr), 118.2 (s, =CH₂), 76.4 (d, ¹*J*_{PC}=100.9 Hz, *CHOH*), 66.5 (d, ²*J*_{PC}=7.3 Hz, *OCH*₂); FABMS (NBA, *m*/*z*, I, %): 393 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 393.0262 (calcd for C₁₈H₁₉BrO₃P: 393.0255); IR (NaCl): v 3207, 2826, 1712, 1590, 1492, 1439, 1217, 1200, 1122, 1092, 1016, 923, 693, 563 cm⁻¹.

4.3.4.2. Second diastereomer. ³¹P NMR (161.97 MHz, CDCl₃): δ 39.9; ¹H NMR (400.13 MHz, CDCl₃): δ 7.89–7.83 (m, 2H, *CH*_{Ar}), 7.61–7.56 (m, 1H, *CH*_{Ar}), 7.49–7.44 (m, 2H, *CH*_{Ar}), 7.37–7.28 (m, 5H, *CH*_{Ar}), 6.92 (dd, ⁴*J*_{PH}=4.8 Hz, ³*J*_{HH}=0.44 Hz, 1H, =*CH*), 6.00 (m, ³*J*_{HH}=5.3 Hz, ³*J*_{HH}=5.4 Hz, ³*J*_{HH}=10.5 Hz, ³*J*_{HH}=17.1 Hz, 1H, =*CH*), 5.45 (m, ²*J*_{HH}=-1.4 Hz, ⁴*J*_{HH}=1.5 Hz, ⁴*J*_{HH}=1.5 Hz, ³*J*_{HH}=17.1 Hz, 1H, =*CH*), 5.45 (m, ²*J*_{HH}=-1.4 Hz, ⁴*J*_{HH}=1.5 Hz, ⁴*J*_{HH}=1.4 Hz, ⁴*J*_{HH}=1.4 Hz, ³*J*_{HH}=10.5 Hz, 1H, =*CH*₂), 5.02 (dd, ²*J*_{PH}=12.1 Hz, ³*J*_{HH}=1.1 Hz, 1H, *CHOH*), 4.74 (m, ³*J*_{PH}=6.9 Hz, ²*J*_{JHH}=-12.9 Hz, ⁴*J*_{HH}=1.5 Hz, ⁴*J*_{HH}=1.4 Hz, ³*J*_{HH}=5.3 Hz, 1H, *OCH*₂), ¹³C NMR (100.61 MHz, CDCl₃): δ 135.1(d, ⁴*J*_{PC}=3.1 Hz, *CH*_{Ar}), 133.1 (d, ⁴*J*_{PC}=3.1 Hz, *CH*_{Ar}), 133.0 (d, ⁶*J*_{PC}=9.8 Hz, *CH*_{Ar}), 128.9 (d, ³*J*_{PC}=2.4 Hz, =*CHP*h), 128.3 (d, ³*J*_{PC}=12.9 Hz, *CH*_{Ar}), 128.0 (d, ⁵*J*_{PC}=1.8 Hz, *CH*_{Ar}), 128.0 (s, *CH*_{Ar}), 126.4 (d, ¹*J*_{PC}=100.9 Hz, *CHOH*), 66.5 (d, ²*J*_{PC}=7.3 Hz, *OCH*₂); FABMS (NBA, *m*/*z*, 1, %): 393 [(M+H)⁺, 100%];

HRMS *m*/*z* (MH⁺) 393.0260 (calcd for C₁₈H₁₉BrO₃P: 393.0255); IR (NaCl): *v* 3210, 1712, 1594, 1490, 1432, 1220, 1188, 1118, 1095, 1013, 920, 748, 699, 570 cm⁻¹.

4.4. General procedure for RCM reactions compounds 8a-b and 9a-g

To a solution of precursor **3a**, **b** or **6a–g** in dry CH_2Cl_2 (0.02 M) was added Grubb's first generation catalyst (2% mol). The mixture was stirred under reflux. The reaction was monitored by ³¹P NMR. If after 30 min starting material remained, the reaction was stirred one more hour. If no evolution occurred, 1% mol of catalyst was added. After consumption of unsaturated precursor, solvent was removed under vacuum and the residue was purified by chromatography.

4.4.1. 2-Hydroxy-2-oxo-1,2-oxaphosphol-3-ene (**8a**). Catalyst: 5%, Eluent: AcOEt/Hexane 8/2 then AcOEt 100%. Yield: 0.215 g (65%).

³¹P NMR (81.02 MHz, Acetone-D₆): δ 42.9; ¹H NMR (400.13 MHz, Acetone-D₆): δ 7.72 (sl, 1H, OH), 7.31 (tdd, ³*J*_{PH}=44.7 Hz, ³*J*_{HH}=8.6 Hz, ³*J*_{HH}=1.7 Hz, 1H, =*C*H), 6.33 (tdd ²*J*_{PH}=34.6 Hz, ³*J*_{HH}=2.4 Hz, 1H *PC*H), 4.82 (ddd, ³*J*_{PH}=6.4 Hz, ³*J*_{HH}=1.7 Hz, ⁴*J*_{HH}=2.4 Hz, 2H, *OCH*₂); ¹³C NMR (100.61 MHz, Acetone-D₆): δ 148.7 (d, ²*J*_{PC}=17.2 Hz, =*C*H), 116.7 (d, ¹*J*_{PC}=166.1 Hz, *PC*H), 70.6 (d, ²*J*_{PC}=14.7 Hz, *OCH*₂); FABMS (NBA, *m*/*z*, I, %): 121 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 121.0054 (calcd for C₃H₆O₃P: 121.0054); IR (KBr): *v* 3425, 3086, 1595, 1322, 1212, 1105, 930, 738, 622 cm⁻¹. Melting point 119 °C (Lit. 110–111 °C).¹⁰

4.4.2. 1-Benzyl-2-ethoxy-2-oxo-1,2-azaphosphol-3-ene (**8b**). Catalyst: 2%, Eluent: AcOEt 100%. Yield: 0.250 g (80%).

³¹P NMR (81.02 MHz, CDCl₃): δ 38.4; ¹H NMR (400.13 MHz, CDCl₃): δ 7.48–7.21 (m, 5H, *CH*_{Ar}), 6.90–6.80 (m, 1H, =*CH*), 6.12–6.04 (m, 1H, *PCH*), 4.40–4.35 (m, 2H, *NCH*₂), 4.23 (dd, ²J_{HH}=–15.2 Hz, ²J_{PH}=9.2 Hz, 1H, *NCH*₂Ph), 4.21 (dd, ²J_{HH}=–15.2 Hz, ²J_{PH}=9.2 Hz, 1H, *NCH*₂Ph), 4.20–4.11 (m, 2H, *OCH*₂), 1.35 (t, ³J_{HH}=7.1 Hz, 3H, *CH*₃); ¹³C NMR (100.61 MHz, CDCl₃): δ 148.7 (d, ²J_{PC}=17.2 Hz, =*CH*), 138.2 (d, ³J_{PC}=2.4 Hz, C_{Ar}), 128.6 and 128.9 (s, *CH*_{Ar}), 127 (s, *CH*_{Ar}), 122.9 (d, ¹J_{PC}=164.2 Hz, *PCH*), 61.2 (d, ²J_{PC}=6.7 Hz, *OCH*₂), 53.1 (d, ²J_{PC}=4.3 Hz, *NCH*₂), 49.1 (d, ²J_{PC}=4.3 Hz, *NCH*₂), 16.3 (d, ³J_{PC}=6.7 Hz, *CH*₃); FABMS (NBA, *m*/*z*, I, %): 238 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 238.1005 (calcd for C₁₂H₁₇NO₂P: 238.0997); IR (NaCl): ν 2977, 1623, 1222, 1074, 1012, 725, 693, 660 cm⁻¹.

4.4.3. 4,5-Dehydro-2-ethoxy-2-oxo-1,2-oxaphosphinane (**9a**). Catalyst: 3.5%, Eluent: AcOEt/Hexane 8/2 then AcOEt 100%. Yield: 0.700 g (87%).

³¹P NMR (101.25 MHz, CDCl₃): δ 20.8; ¹H NMR (250.13 MHz, CDCl₃): δ 5.74–5.67 (m, 2H, *CH*=*CH*), 4.89–4.71 (m, 2H, *OCH*₂), 4.20–4.11 (m, 2H, *CH*₂), 2.59–2.46 (m, 2H, *PCH*₂), 1.35 (t, ³*J*_{HH}=7.1 Hz, 3H, *CH*₃); ¹³C NMR (62.90 MHz, CDCl₃): δ 125.3 (d, ³*J*_{PC}=17.2 Hz, =*CH*), 120.7 (d, ²*J*_{PC}=9.6 Hz, =*CH*), 69.2 (d, ²*J*_{PC}=7.7 Hz, *OCH*₂), 61.7 (d, ²*J*_{PC}=6.6 Hz, *OCH*₂), 22.7 (d, ¹*J*_{PC}=133.4 Hz, *PCH*₂), 16.7 (d, ³*J*_{PC}=5.7 Hz, *CH*₃); FABMS (NBA, *m*/*z*, I, %): 163 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 163.0547 (calcd for C₆H₁₂O₃P: 163.0524); IR (NaCl): *ν* 3512, 3070, 2873, 1452, 1230, 1181, 1063, 954, 840 cm⁻¹.

4.4.4. 1-Benzyl-2-ethoxy-4,5-dehydro-2-oxo-1,2-azaphosphinane (**9c**). Catalyst: 2.5%, Eluent: CH₂Cl₂/EtOH 97/3. Yield: 0.802 g (88%).

³¹P NMR (101.25 MHz, CDCl₃): δ 25.4; ¹H NMR (400.13 MHz, CDCl₃): δ 7.36–7.25. (m, 5H, *CH*_{Ar}), 5.72–5.55 (m, 2H, *CH*=*CH*), 4.61 (dd, ³*J*_{PH}=10.6 Hz, ²*J*_{HH}=-14.7 Hz, 1H, *NCH*₂), 4.08–4.00 (m, 3H,OCH₂ and *NCH*₂), 3.47–3.66 (m, 2H, *NCH*₂), 2.69–2.39 (m, 2H, *PCH*₂), 1.32 (t, ³*J*_{HH}=7.0 Hz, *CH*₃); ¹³C NMR (62.90 MHz, CDCl₃): δ 138.2 (d, ³*J*_{PC}=5.4 Hz, *C*_{Ar}), 128.8 (s, *CH*_{Ar}), 128.7 (s, *CH*_{Ar}), 126.2 (d,

 $\begin{array}{l} J_{PC} = 15.0 \text{ Hz}, = CH), 127.7 \text{ (s, } CH_{Ar}), 120.6 \text{ (d, } J_{PC} = 10.3 \text{ Hz}, = CH), 61.0 \\ \text{(d, } ^2J_{PC} = 6.5 \text{ Hz}, OCH_2), 50.2 \text{ (s, } NCH_2), 49.5 \text{ (s, } NCH_2), 24.7 \text{ (d, } \\ ^1J_{PC} = 126.9 \text{ Hz}, PCH_2), 16.9 \text{ (d, } ^3J_{PC} = 6.1 \text{ Hz}, CH_3); \text{FABMS (NBA, } m/z, \text{ I}, \\ \text{\%): } 252 \text{ [(M+H)^+, } 100\%]; \text{ HRMS } m/z \text{ (MH^+) } 252.1148 \text{ (calcd for } C_{13}H_{19}O_2\text{NP: } 252.1143); \text{ IR (NaCl): } \nu \text{ 3070, } 2988, 2960, 1612, \\ 1219,1085, 1022, 724, 690 \text{ cm}^{-1}. \end{array}$

4.4.5. 4,5-Dehydro-3-hydroxy-2-phenyl-2-oxo-1,2-oxaphosphinane (**9d**). Catalyst: 7%, Eluent: CH₂Cl₂/EtOH 98/2 Yield: two fractions of diastereomers 0.408 g and 0.320 mg (87%).

4.4.5.1. First diastereomer. ³¹P NMR (161.97 MHz, CDCl₃): δ 29.3; ¹H NMR (400.13 MHz, CDCl₃): δ 7.82–7.77 (m, 2H, *CH*_{Ar}), 7.55–7.51 (m, 1H, *CH*_{Ar}), 7.45–7.40 (m, 2H, *CH*_{Ar}), 5.88 (m, ³*J*_{PH}=19.0 Hz, ³*J*_{HH}=11.2 Hz, ³*J*_{HH}=2.5 Hz, ⁴*J*_{HH}=2.4 Hz, ⁴*J*_{HH}=2.4 Hz, 1H, =*CH*), 5.75 (m, ⁴*J*_{PH}=3.0 Hz, ³*J*_{HH}=11.2 Hz, ⁴*J*_{HH}=2.6 Hz, ³*J*_{HH}=2.4 Hz, ³*J*_{HH}=2.6 Hz, 1H, =*CH*), 4.89 (m, ³*J*_{PH}=3.1 Hz, ²*J*_{HH}=-16.7 Hz, ³*J*_{HH}=2.6 Hz, ⁴*J*_{HH}=2.4 Hz, ⁵*J*_{HH}=2.7 Hz, 1H, *OCH*₂), 4.63 (m, ³*J*_{PH}=15.4 Hz, ²*J*_{HH}=-16.7 Hz, ³*J*_{HH}=2.4 Hz, ⁴*J*_{HH}=2.6 Hz, ³*J*_{HH}=2.6 Hz, ¹H, *OCH*₂), 4.45 (m, ²*J*_{PH}=3.1 Hz, ⁴*J*_{HH}=2.6 Hz, ³*J*_{HH}=2.5 Hz, ⁵*J*_{HH}=2.6 Hz, ⁵*J*_{HH}=2.7 Hz, 1H, *CHOH*); ¹³C NMR (100.61 MHz, CDCl₃): δ 133.1 (d, ⁴*J*_{PC}=2.9 Hz, *CH*_{Ar}), 131.7 (d, ³*J*_{PC}=10.2 Hz, *CH*_{Ar}), 128.7 (d, ³*J*_{PC}=13.9 Hz, *CH*_{Ar}), 128.5 (d, ¹*J*_{PC}=134.7 Hz, *C*_{Ar}), 128.0 (d, ²*J*_{PC}=2.9 Hz, *CH*), 125.4 (d, ²*J*_{PC}=11.7 Hz, =*CH*), 65.6 (d, ²*J*_{PC}=7.3 Hz, *OCH*₂), 62.5 (d, ¹*J*_{PC}=102.4 Hz, *CHOH*); FABMS (NBA, *m*/*z*, 1, %): 211 [(M+H)⁺, 100%], 193 [(M-OH)⁺, 25%]; HRMS *m*/*z* (MH⁺) 211.0527 (calcd for C₁₀H₁₂O₃P: 211.0524); IR (NaCI): *v* 3252, 3063, 2880, 1443, 1272, 1234, 1175, 1119, 1099, 1063, 954, 743, 696 cm⁻¹.

4.4.5.2. Second diastereomer. ³¹P NMR (161.97 MHz, CDCl₃): δ 34.5; ¹H NMR (400.13 MHz, CDCl₃): δ 7.81–7.76 (m, 2H, *CH*_{Ar}), 7.50–7.45 (m, 1H, *CH*_{Ar}), 7.37–7.33 (m, 2H, *CH*_{Ar}), 5.96–5.86 (m, 1H, =*CH*), 5.79–5.75 (m, 1H, =*CH*), 4.83–4.76 (m, 1H, *OCH*₂), 4.62–4.57 (m, 1H, *OCH*₂), 4.32–4.21 (m, 1H, *CHOH*); ¹³C NMR (100.61 MHz, CDCl₃): δ 133.0 (d, ⁴*J*_{PC}=2.2 Hz, *CH*_{Ar}), 132.5 (d, ²*J*_{PC}=9.5 Hz, *CH*_{Ar}), 128.4 (d, ³*J*_{PC}=12.4 Hz, *CH*_{Ar}), 127.9 (d, *J*_{PC}=13.5 Hz, =*CH*), 126.9 (d, ¹*J*_{PC}=13.9 Hz, *C*_{Ar}), 126.4 (d, *J*_{PC}=2.2 Hz, =*CH*), 66.5 (d, ²*J*_{PC}=7.3 Hz, *OCH*₂), 61.7 (d, ¹*J*_{PC}=106.1 Hz, *CHOH*); FABMS (NBA, *m*/*z*, I, %): 211 [(M+H)⁺, 100%]; HRMS *m*/*z* (MH⁺) 211.0527 (calcd for C₁₀H₁₂O₃P: 211.0524); IR (NaCl): *v* 3300, 1523, 1225, 1163, 1121, 1084, 1063, 922, 726 cm⁻¹; Melting point 158 °C.

4.4.6. 4,5-Dehydro-3-hydroxy-3-methyl-2-phenyl-2-oxo-1,2-oxaphosphinane (**9f**). Catalyst: 10%, Eluent: $CH_2Cl_2/EtOH$ 98/2. Yield: 0.444 g (50%).

³¹P NMR (CDCl₃, 161.97 MHz): δ 38.5 (55% dia. 1), 32.1 (45% dia. 2); ¹H NMR (CDCl₃, 400.13 MHz): δ 7.81–7.76 (m, 2H, CH_{Ar}), 7.50–7.45 (m, 1H, CH_{Ar}), 7.37–7.33 (m, 2H, CH_{Ar}), 5.96–5.86 (m, 2H, CH=CH), 5.10–5.02 (m, 1H, OCH_2), 4.90–4.76 (m, 1H, OCH_2), 1.56 (d, ³ $J_{PH}=14.8$ Hz, 3H, CH_3); ¹³C NMR (CDCl₃, 100.61 MHz): *diastereomer*

1: δ 133.1 (d, ${}^{4}J_{PC}$ =2.2 Hz, CH_{Ar}), 132.4 (d, ${}^{2}J_{PC}$ =9.5 Hz, CH_{Ar}), 129.0 (d, ${}^{3}J_{PC}$ =12.5 Hz, CH_{Ar}), 128.0 (d, J_{PC} =13.5 Hz, =CH), 126.9 (d, ${}^{1}J_{PC}$ =136.3 Hz, C_{Ar}), 126.4 (d, J_{PC} =2.2 Hz, =CH), 66.5 (d, ${}^{2}J_{PC}$ =7.4 Hz, OCH_2), 63.4 (d, ${}^{1}J_{PC}$ =112.9 Hz, PCOH), 22.6 (d, ${}^{2}J_{PC}$ =3.9 Hz, CH_3); diastereomer 2: δ 134.1 (d, ${}^{4}J_{PC}$ =2.2 Hz, CH_{Ar}), 133.2 (d, ${}^{2}J_{PC}$ =10.2 Hz, CH_{Ar}), 130.2 (d, ${}^{3}J_{PC}$ =11.3 Hz, CH_{Ar}), 128.5 (d, J_{PC} =14.2 Hz, =CH), 127.2 (d, ${}^{1}J_{PC}$ =132.5 Hz, C_{Ar}), 126.2 (d, J_{PC} =2.2 Hz, =CH), 64.2 (d, ${}^{2}J_{PC}$ =7.3 Hz, OCH_2), 61.7 (d, ${}^{1}J_{PC}$ =114.5 Hz, PCOH), 24.2 (d, ${}^{2}J_{PC}$ =4.4 Hz, CH_3); FABMS (NBA, m/z, I, %): 225 [(M+H)⁺, 100%]; HRMS m/z (MH⁺) 225.0701 (calcd for C₁₁H₁₄O₃P: 225.0680); IR (NaCl): ν 3300, 3100, 2900, 1550, 1272, 1225, 1172, 1130, 1099, 1050, 954, 743, 696 cm⁻¹.

Acknowledgements

This research was supported by Bayer CropScience SA and the Région Languedoc-Roussillon.

References and notes

- (a) Westheimer, F. H. Science 1987, 235, 1173; (b) Seto, H.; Kuzuyama, T. Nat. Prod. Rep. 1999, 16, 589; For more representative examples of phosphoruscontaining pharmaceutical agents, see: (c) Kafarski, P.; Lejczak, B. Phosphorus Sulfur Silicon Relat. Elem. 1991, 63, 193; (d) Colvin, O. M. Curr. Pharm. Des. 1999, 5, 555; (e) Zon, G. Prog. Med. Chem. 1982, 19, 205; (f) Fields, S. C. Tetrahedron 1999, 55, 12237; (g) Kafarski, P.; Lejczak, B. Curr. Med. Chem. 2001, 1, 301; (h) Mukherjee, S.; Huang, C.; Guerra, F.; Wang, K.; Oldfield, E. J. Am. Chem. Soc. 2009, 131, 8374.
- 2. Fourgeaud, P.; Vors, J. P.; Virieux, D. Targets in Heterocycl. Systems 2005, 9, 254.
- For reviews of RCM see: (a) Trnka, T. M.; Grubbs, R. H. Acc. Chem. Res. 2001, 34, 18; (b) Furstner, A. Angew. Chem., Int. Ed. 2000, 39, 3012; (c) Grubbs, R. H. Handbook of Metathesis; Wiley-VCH: Weinheim, 2003.
- For review of RCM in heterocyclic phosphorus compound synthesis see: (a) McReynolds, M. D.; Dougherty, J. M.; Hanson, P. R. *Chem. Rev.* 2004, 104, 2239; (b) Sieck, S. R.; McReynolds, M. D.; Schroeder, C. E.; Hanson, P. R. J. Organomet. *Chem.* 2006, 691, 5307.
- (a) Ahmed, M.; Atkinson, C. E.; Barrett, A. G. M.; Malagu, K.; Procopiou, P. A. Org. Lett. 2003, 5, 669; (b) Hetherington, L.; Greedy, B.; Gouverneur, V. Tetrahedron 2000, 56, 2053; (c) Hanson, P. R.; Stoianova, D. S. Tetrahedron Lett. 1998, 39, 3939.
- (a) Stoianova, D. S.; Whitehead, A.; Hanson, P. R. J. Org. Chem. 2005, 70, 5880;
 (b) Stoianova, D. S.; Hanson, P. R. Org. Lett. 2001, 3, 3285 Other groups where interested by such intermediates: (c) Zhang, H.; Tsukuhara, R.; Tigyi, G.; Prestwich, G. D. J. Org. Chem. 2006, 71, 6061.
- Pirat, J.-L.; Virieux, D.; Clarion, L.; Volle, J.-N.; Bakalara, N.; Mersel, M.; Montbrun, J.; Cristau, H.-J. PCT Int. Appl. WO09004096, 2009.
- 8. Afarinka, K.; Yu, H. Tetrahedron Lett. 2003, 44, 781.
- 9. Texier-Boullet, F.; Foucaud, A. Synthesis 1982, 165.
- 10. Machida, Y.; Saito, I. J. Org. Chem. 1979, 44, 865.
- 11. Weinreb, S. M.; Chao, W. Org. Lett. 2003, 5, 2505.
- 12. Fox, H. H.; Lee, J. K.; Park, L. Y.; Schrock, R. R. Organometallics 1993, 12, 759.
- (a) Harvey, J. S.; Malcolmson, S. J.; Dunne, K. S.; Meek, S. J.; Thompson, A. L.; Schrock, R. R.; Hoveyda, A. H.; Gouverneur, V. Angew. Chem. 2009, 48, 762; (b) Vinokurov, N.; Michrowska, A.; Szmigielska, A.; Drzazga, Z.; Wojciuk, G.; Demchuk, O. M.; Grela, K.; Pietrusiewicz, K. M.; Butenschön, H. Adv. Synth. Catal. 2006, 348, 931.
- (a) Davies, S. R.; Mitchell, M. C.; Cain, C. P.; Devitt, P. G.; Taylor, R. J.; Kee, T. P. J. Organomet. Chem. **1998**, 550, 29; (b) Merino, P.; Marques-Lopez, E.; Herrera, R. P. Angew. Chem. **2008**, 47, 5646.